Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Author Correction: An atlas of genetic influences on osteoporosis in humans and mice.

Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Chai RC, Vulpescu NA, Forgetta V, Kleinman A, Mohanty ST, Sergio CM, Quinn J, Nguyen-Yamamoto L, Luco AL, Vijay J, Simon MM, Pramatarova A, Medina-Gomez C, Trajanoska K, Ghirardello EJ, Butterfield NC, Curry KF, Leitch VD, Sparkes PC, Adoum AT, Mannan NS, Komla-Ebri DSK, Pollard AS, Dewhurst HF, Hassall TAD, Beltejar MG; 23andMe Research Team, Adams DJ, Vaillancourt SM, Kaptoge S, Baldock P, Cooper C, Reeve J, Ntzani EE, Evangelou E, Ohlsson C, Karasik D, Rivadeneira F, Kiel DP, Tobias JH, Gregson CL, Harvey NC, Grundberg E, Goltzman D, Adams DJ, Lelliott CJ, Hinds DA, Ackert-Bicknell CL, Hsu YH, Maurano MT, Croucher PI, Williams GR, Bassett JHD, Evans DM, Richards JB.

Nat Genet. 2019 May;51(5):920. doi: 10.1038/s41588-019-0415-x.

PMID:
30988516
2.

An atlas of genetic influences on osteoporosis in humans and mice.

Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Chai RC, Vulpescu NA, Forgetta V, Kleinman A, Mohanty ST, Sergio CM, Quinn J, Nguyen-Yamamoto L, Luco AL, Vijay J, Simon MM, Pramatarova A, Medina-Gomez C, Trajanoska K, Ghirardello EJ, Butterfield NC, Curry KF, Leitch VD, Sparkes PC, Adoum AT, Mannan NS, Komla-Ebri DSK, Pollard AS, Dewhurst HF, Hassall TAD, Beltejar MG; 23andMe Research Team, Adams DJ, Vaillancourt SM, Kaptoge S, Baldock P, Cooper C, Reeve J, Ntzani EE, Evangelou E, Ohlsson C, Karasik D, Rivadeneira F, Kiel DP, Tobias JH, Gregson CL, Harvey NC, Grundberg E, Goltzman D, Adams DJ, Lelliott CJ, Hinds DA, Ackert-Bicknell CL, Hsu YH, Maurano MT, Croucher PI, Williams GR, Bassett JHD, Evans DM, Richards JB.

Nat Genet. 2019 Feb;51(2):258-266. doi: 10.1038/s41588-018-0302-x. Epub 2018 Dec 31. Erratum in: Nat Genet. 2019 May;51(5):920.

3.

A mutation in the viral sensor 2'-5'-oligoadenylate synthetase 2 causes failure of lactation.

Oakes SR, Gallego-Ortega D, Stanford PM, Junankar S, Au WWY, Kikhtyak Z, von Korff A, Sergio CM, Law AMK, Castillo LE, Allerdice SL, Young AIJ, Piggin C, Whittle B, Bertram E, Naylor MJ, Roden DL, Donovan J, Korennykh A, Goodnow CC, O'Bryan MK, Ormandy CJ.

PLoS Genet. 2017 Nov 8;13(11):e1007072. doi: 10.1371/journal.pgen.1007072. eCollection 2017 Nov.

4.

ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells.

Gallego-Ortega D, Ledger A, Roden DL, Law AM, Magenau A, Kikhtyak Z, Cho C, Allerdice SL, Lee HJ, Valdes-Mora F, Herrmann D, Salomon R, Young AI, Lee BY, Sergio CM, Kaplan W, Piggin C, Conway JR, Rabinovich B, Millar EK, Oakes SR, Chtanova T, Swarbrick A, Naylor MJ, O'Toole S, Green AR, Timpson P, Gee JM, Ellis IO, Clark SJ, Ormandy CJ.

PLoS Biol. 2015 Dec 30;13(12):e1002330. doi: 10.1371/journal.pbio.1002330. eCollection 2015 Dec.

5.

Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells.

Rogers S, Gloss BS, Lee CS, Sergio CM, Dinger ME, Musgrove EA, Burgess A, Caldon CE.

Cell Div. 2015 Feb 19;10:1. doi: 10.1186/s13008-015-0007-9. eCollection 2015.

6.

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.

Kang J, Sergio CM, Sutherland RL, Musgrove EA.

BMC Cancer. 2014 Jan 20;14:32. doi: 10.1186/1471-2407-14-32.

7.

BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.

Stone A, Cowley MJ, Valdes-Mora F, McCloy RA, Sergio CM, Gallego-Ortega D, Caldon CE, Ormandy CJ, Biankin AV, Gee JM, Nicholson RI, Print CG, Clark SJ, Musgrove EA.

Mol Cancer Ther. 2013 Sep;12(9):1874-85. doi: 10.1158/1535-7163.MCT-13-0012. Epub 2013 Jul 16.

8.

Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.

Caldon CE, Sergio CM, Burgess A, Deans AJ, Sutherland RL, Musgrove EA.

Cell Cycle. 2013 Feb 15;12(4):606-17. doi: 10.4161/cc.23512. Epub 2013 Jan 16.

9.

Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.

Caldon CE, Sergio CM, Sutherland RL, Musgrove EA.

Cell Cycle. 2013 Feb 15;12(4):596-605. doi: 10.4161/cc.23409. Epub 2013 Jan 16.

10.

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA.

Mol Cancer Ther. 2012 Jul;11(7):1488-99. doi: 10.1158/1535-7163.MCT-11-0963. Epub 2012 May 7.

11.

Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc.

Caldon CE, Sergio CM, Schütte J, Boersma MN, Sutherland RL, Carroll JS, Musgrove EA.

Mol Cell Biol. 2009 Sep;29(17):4623-39. doi: 10.1128/MCB.00269-09. Epub 2009 Jun 29.

12.

Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer.

Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, Alles MC, Pinese M, Caldon CE, Schütte J, Gardiner-Garden M, Ormandy CJ, McArthur G, Butt AJ, Sutherland RL.

PLoS One. 2008 Aug 20;3(8):e2987. doi: 10.1371/journal.pone.0002987.

13.

Identification of downstream targets of estrogen and c-myc in breast cancer cells.

Musgrove EA, Sergio CM, Anderson LR, Inman CK, McNeil CM, Alles MC, Gardiner-Garden M, Ormandy CJ, Butt AJ, Sutherland RL.

Adv Exp Med Biol. 2008;617:445-51. doi: 10.1007/978-0-387-69080-3_43.

PMID:
18497068
14.

The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.

Butt AJ, Sergio CM, Inman CK, Anderson LR, McNeil CM, Russell AJ, Nousch M, Preiss T, Biankin AV, Sutherland RL, Musgrove EA.

Breast Cancer Res. 2008;10(2):R28. doi: 10.1186/bcr1985. Epub 2008 Mar 29.

15.

Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor.

McGowan EM, Russell AJ, Boonyaratanakornkit V, Saunders DN, Lehrbach GM, Sergio CM, Musgrove EA, Edwards DP, Sutherland RL.

Cancer Res. 2007 Sep 15;67(18):8942-51.

16.

Test of models of achromatic transparency.

Sergio CM.

Perception. 2006;35(12):1611-24.

PMID:
17283928
17.

c-Myc overexpression and endocrine resistance in breast cancer.

McNeil CM, Sergio CM, Anderson LR, Inman CK, Eggleton SA, Murphy NC, Millar EK, Crea P, Kench JG, Alles MC, Gardiner-Garden M, Ormandy CJ, Butt AJ, Henshall SM, Musgrove EA, Sutherland RL.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):147-55. Epub 2006 Oct 18.

PMID:
17052904
18.

Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1.

Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B.

Mol Cell Endocrinol. 2005 Jan 14;229(1-2):161-73.

PMID:
15607540
19.

Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1.

Swarbrick A, Akerfeldt MC, Lee CS, Sergio CM, Caldon CE, Hunter LJ, Sutherland RL, Musgrove EA.

Oncogene. 2005 Jan 13;24(3):381-9.

PMID:
15489884
20.

Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.

Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL.

Endocr Relat Cancer. 2003 Jun;10(2):179-86. Review.

PMID:
12790780

Supplemental Content

Loading ...
Support Center